Positron Emission Tomography (PET) Working Group Looks to Build on Success in 2024

Washington, D.C. – The Medical Imaging & Technology Alliance (MITA) – the collective voice of medical imaging and radiopharmaceutical manufacturers, innovators, and product developers  – is celebrating the significant advancements in Positron Emission Tomography (PET) and radiopharmaceutical access and awareness, in large part due to advocacy efforts driven by the twenty participating members of the MITA PET Working Group this year.

MITA worked with congressional champions to introduce the Facilitating Innovative Nuclear Diagnostics Act of 2023 (H.R. 1199/S.1544) in both the House, where it currently has 35 cosponsors and in the Senate, where seven bipartisan senators have loaned their support. Broader support for the legislation also continues to grow, as this year, over 120 organizations joined together to advocate for the passage of this legislation.

The group has also led efforts to urge the Centers for Medicare and Medicaid Services (CMS) to reform payment policy for diagnostic radiopharmaceuticals, which would improve access to innovative and advanced imaging for all Medicare beneficiaries.

“There’s no doubt that our achievements this year set our MITA PET Working Group up for continued success in 2024,” said Sue Bunning, Managing Director of Positron Emission Tomography for MITA. “Thanks to the commitment and dedication of our membership, I know we’ll continue to make inroads with key congressional leaders and policymakers to fix flawed payment for radiopharmaceuticals once and for all. This work is too important to patients for us to take our foot off the gas now and I’m pleased all twenty of our member companies will continue our partnership with NEMA to advance this effort next year.”

###